Immune subset analyses revealed that the combination therapy not only enhanced CD4+Foxp3- T-cell expansion at the metastatic tumor site (lung) and in the periphery (spleen and DLN), but also augmented memory formation compared to the untreated and monotherapy controls. This evidence concerns the gene FOXP3 and metastatic neoplasm.